Abortion Bans Do NOT Impact Maternal Mortality Rates

April 3, 2026—The Journal of American Medical Association has published a Report that concludes that abortion bans do not increase maternal mortality nationwide as a whole or state specifically. Data used was collected by the National Center for Health Statistics, a unit of the Center for Disease Control.

The Report concludes: "This cohort study found that abortion bans were not associated with statistically significant overall or state-specific increases in pregnancy-associated mortality."  

As more and more states have passed legislation banning abortion after certain cut-off thresholds, such as heartbeat detection or number of weeks in gestation, so called "Pro-Choice" organizations have increasingly claimed that these bans threaten the mortality and health of pregnant women. 

The Gender Equity Policy Institute has been at the forefront of these claims which have been touted extensively in an effort to sway public opinion and legislation away from bans of abortion. 

Now these claims have been refuted by credible research by medical doctors and other science professionals.

You can read the entire Report here:  US Abortion Bans & Mortality

Hawley Bill Banning Chemical Abortion Drug Gains Momentum

March 25, 2026, WASHINGTON — U.S. Senator Josh Hawley (R-Mo.) sent a letter to his Republican colleagues in the Senate, urging them to join his new legislation to ban the chemical abortion drug mifepristone and empower women harmed by the drug to sue its manufacturers. The outreach comes after Senator Hawley’s legislation gained 3 new cosponsors: Senators John Cornyn (R-Texas), Marsha Blackburn (R-Tenn.), and Ted Budd (R-N.C.). Companion legislation sponsored by Congresswoman Diana Harshbarger (TN-01) has also picked up multiple co-sponsors in the House.

Senator Hawley wrote, “I write regarding a grave threat to the health and safety of American women: the chemical abortion drug known as mifepristone. The evidence is now clear. Mifepristone is almost always fatal to the unborn child, but it is also significantly dangerous for women. The drug companies that make this drug know this, but continue to profit from the drug’s nearly unregulated distribution, largely insulated from liability. Congress can no longer ignore these dangers.” 

He continued, “At a recent event on Capitol Hill, I invited women who took mifepristone to share their experiences. These women were pressured or coerced into taking the drug, often with repeated assurances that the drug was safe, that they would be able to resume their normal lives in a matter of days. The reality was far different. One woman spent a month in a medically induced coma. Another described bleeding uncontrollably with no one to help. They still suffer from the trauma to this day. But no woman who has suffered from this drug has any meaningful option to recover from the two drug companies who make it, mislead about its effects—and profit from it to the tune of billions of dollars. That should change.”

Senator Hawley concluded, “I have introduced legislation to withdraw FDA approval of mifepristone for use in an abortion. My bill would also allow women harmed by mifepristone used for an abortion to sue the manufacturers for damages. Congress has the power—and the duty—to protect women from the dangers of chemical abortion and from the corporations who would exploit them. I hope that you will join me in this effort.”

This legislation, called the Safeguarding Women from Chemical Abortion Act, is supported by Susan B. Anthony Pro-Life America, Family Research Council, Alliance Defending Freedom, Concerned Women for America, Live Action, Students for Life of America, Ethics and Public Policy Center, AAPLOG Action, March for Life Action, National Right to Life, Priests for Life, Ethics and Religious Liberty Commission, Thomas More Society, Missouri Right to Life, Choose Life of Missouri, and Reach Reproductive Health.